Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

terminated120%
active_not_recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_1

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

NCT02483312
completedphase_1

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

NCT01266616
completedphase_1

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

NCT00528489
completedphase_1

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

NCT00004070
terminatedphase_1

Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

NCT00057486

Clinical Trials (5)

Showing 5 of 5 trials
NCT02483312Phase 1

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Active Not Recruiting
NCT01266616Phase 1

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Completed
NCT00528489Phase 1

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Completed
NCT00004070Phase 1

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Completed
NCT00057486Phase 1

Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5